patient

The company said it could not find enough test patients in its Phase Ib clinical trial for the last six months. The disease afflicts mainly children.

StemCells Inc. (STEM) is down just over 9% but it is paring losses from its opening bell skid to 73 cents, sparked by the company's announcement that it is ending its program for a stem-cell treatment for Batten disease.

Health care shares are trending higher, while Abbott Laboratories (ABT) is seeing solid gains after reporting study results. In sector news, Abbott Laboratories (ABT) today announced that data from its Endovascular Valve Edge-to-E

Each stock option has an exercise price per share equal to $11.83, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commenceme

Optimer Pharmaceuticals (OPTR) says that on March 31, its Board approved the grant of inducement stock options to purchase an aggregate of 258,000 shares of common stock to 7 new employees.

Health care shares are down in mid-day trading, but Human Genome Sciences (HGSI) bucks the trend, after getting a key approval from the U.S. Food and Drug Administration. the FDA approved BENLYSTA to treat adult patients with acti

That could signal a possible delay in a combination product analysts expect will top $1 billion in sales, the report says.

Novartis ADRs are down 0.52%, or $0.30, to $56.87.

ADRs of Novartis (NVS) are down after Bloomberg, citing U.S. regulators, reported that the company's treatment for a common lung problem may not be in two doses.

Dr. Barry Polisky, Chief Scientific Officer at Marina, said in a statement: "These results further demonstrate the utility of our DiLA2 delivery technology for local administration."

Marina Biotech shares are up 7.47%, to $0.731.

Shares of Marina Biotech (MRNA) are higher after company data was presented demonstrating significant knockdown of target mRNA in an orthotopic model of malignant ascites with its proprietary UsiRNA construct and DiLA2-based deliv

Harris (HRS) announced today that it plans to acquire Carefx, the developer of Fusionfx, a health care and patient information system used across North America, Europe and Asia in more than 800 hospitals, healthcare systems and he

Teva said results from a Phase III study of QNAZE HFA, its nasal aerosol corticosteroid in development to treat perennial allergic rhinitis (PAR) and seasonal allergic rhinitis, achieved all primary and secondary efficacy endpoint

Teva shares are down 0.9%, or $0.46, to $51.56.

Teva Pharmaceuticals (TEVA) shares are down fractionally, despite positive drug trial news.

Revenue Cycle Manager enables error correction at every stage, unlike legacy applications that resolve errors at the end-stages of the revenue cycle, or point solutions that take limiting approaches at some stages, the company sai

Shares are down 0.36% or $38.47.

Pegasystems (PEGA) today announced the launch of its new Revenue Cycle Manager solution for the health care market, which it says allows health care systems to streamline patient billing, boost cash flow and drive down operational

The Plaintiffs in the lawsuit, three independent pharmacies, have accused CVS of obtaining patient information from independent pharmacies and then using that information to cause patients to purchase their medicine at CVS.

CVS Caremark (CVS) has been sued by North Carolina pharmacies, which have alleged that CVS violated the North Carolina Pharmacy of Choice Act, as well as committing unfair and deceptive business practices.